Zhejiang University has disclosed transient receptor potential cation channel subfamily M member 2 (TRPM2) antagonists reported to be useful for the treatment of stroke and ischemia-reperfusion injury, among others.
Immuneering Corp. has received FDA clearance of its IND application for IMM-1-104, paving the way for the company to initiate a phase I/IIa trial of this oral, once-daily small molecule in development for the treatment of advanced RAS-mutant solid tumors.
Recent evidence suggests that spironolactone, a mineralocorticoid receptor antagonist, may modulate alcohol seeking and consumption, for which current therapies are limited.
Researchers from the University of Queensland have published preclinical data on the novel glycopeptide antibiotic MCC-5145, being developed for the treatment of gram-positive bacterial infections.
Researchers from Lantern Pharma Inc. presented preclinical data for the small-molecule DNA-damaging agent LP-284, being developed for the treatment of hematological cancers.
Antimicrobial peptides (AMPs) are a type of active peptide produced by the organism that are important host-defense factors, with broad-spectrum antibacterial properties, as well as significant properties such as antifungal and antiviral activity and immune regulation, among others.
Preclinical research led by the University Hospital Würzburg in Germany shows early promise for chimeric antigen receptor (CAR) T-cell therapies to treat invasive pulmonary aspergillosis, a serious fungal infection with limited current treatment options.
The Nobel Prize in Physiology or Medicine 2022 was awarded to Svante Pääbo today "for his discoveries concerning the genomes of extinct hominins and human evolution." Pääbo, who is currently the director of the Max Planck Institute for Evolutionary Anthropology in Leipzig, Germany, and his colleagues overcame extreme technical challenges to sequence the DNA of ancient hominids – because after tens of thousands of years, there is no such thing as aging well for DNA.
Terns Pharmaceuticals Inc. has patented thyroid hormone receptor β (THRβ) agonists reported to be useful for the treatment of nonalcoholic steatohepatitis.
RSS
